Loading
Latest filing published 05 Dec 2025 for Enanta Pharmaceuticals INC, €3,948.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Kathleen S. Capps in Enanta Pharmaceuticals Inc. In total, 4 filings cover trades dated from 25 November 2025 to 5 December 2025.
The open-market record consists of 2 sales worth €6,437, with no purchase. The rest of the record consists of 2 share grants.
On 5 December 2025 came the latest disclosure, an open-market sale for €3,948 in Enanta Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations